Last reviewed 2026-04-20 · How we verify

Keppra

Keppra, marketed by the Masonic Cancer Center, University of Minnesota, is an established treatment for epilepsy characterized by intractable complex partial seizures. The drug's key strength lies in its well-documented efficacy and safety profile, supported by its current market presence. The primary risk is the key composition patent expiry in 2028, which could lead to increased competition from generics.

At a glance

Approved indications

• Epilepsy characterized by intractable complex partial seizures
• Myoclonic Epilepsy Adjunct Treatment
• Partial Epilepsy Treatment Adjunct
• Simple partial seizure
• Status epilepticus
• Tonic-Clonic Epilepsy Treatment Adjunct

Common side effects

• Somnolence
• Asthenia
• Infection
• Dizziness
• Fatigue
• Aggression
• Nasal congestion
• Decreased appetite
• Irritability

Key clinical trials

• Levetiracetam Three Times Daily in Epilepsy (PHASE3)
• Prophylactic Anti-Seizure Medication vs No Anti-Seizure Medication for Patients With Primary Motor Cortex Brain Metastases (PHASE2)
• Ketamine add-on Therapy for Established Status Epilepticus Treatment Trial (KESETT) (PHASE3)
• Levetiracetam for Persons at Risk for Alzheimer's Disease (PHASE2)
• A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation (PHASE2)
• High Dose Ruxolitinib and Allogeneic Stem Cell Transplantation in Myelofibrosis Patients With Splenomegaly (PHASE2)
• B6 Administration for Levetiracetam-Associated Neurobehavioral Changes and Epilepsy (NA)
• Evaluation of Levetiracetam's Effectiveness and Tolerability for Treating Epilepsy in Older Adults (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.